Carregant...
Assessment of Response to B-Cell Depletion Using Rituximab in Cutaneous Lupus Erythematosus
IMPORTANCE: Cutaneous lupus erythematosus (CLE) can be severe and treatment resistant. B-cell depletion therapy (BCDT) with rituximab is well recognized in organ involvement in systemic lupus erythematosus (SLE), but its efficacy in cutaneous manifestations is less well established. OBJECTIVE: To ev...
Guardat en:
| Publicat a: | JAMA Dermatol |
|---|---|
| Autors principals: | , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
American Medical Association
2018
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6583321/ https://ncbi.nlm.nih.gov/pubmed/30383114 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamadermatol.2018.3793 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|